首页> 美国卫生研究院文献>Blood >Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias
【2h】

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias

机译:WT-1新型肽的定位以及目前的HLA等位基因这些等位基因诱导具有针对WT-1 +白血病的细胞毒活性的表位特异性HLA限制性T细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Wilms tumor protein (WT-1) is widely recognized as a tumor antigen that is expressed differentially by several malignancies. However, WT-1 peptides known to induce tumoricidal T cells are few. In the present study, we evaluated T-cell responses of 56 healthy donors to in vitro sensitization with autologous APCs loaded with a pool of overlapping 15-mer peptides spanning the sequence of WT-1. Thereafter, we mapped the WT-1 peptides eliciting responses in each individual, defined the immunogenic peptides, and identified their presenting HLA alleles. We report 41 previously unreported epitopes of WT-1: 5 presented by class II and 36 by class I alleles, including 10 that could be presented by more than 1 class I allele. IFNγ+ T cells responding to 98% of the class I and 60% of the class II epitopes exhibited HLA-restricted cytotoxicity against peptide-loaded targets. T cells specific for 36 WT-1 peptides were evaluable for leukemocidal activity, of which 27 (75%) lysed WT-1+ leukemic targets sharing their restricting HLA allele. Each epitope identified induced T-cell responses in most donors sharing the epitopes' presenting allele; these responses often exceeded responses to flanking peptides predicted to be more immunogenic. This series of immunogenic epitopes of WT-1 should prove useful for immunotherapies targeting WT-1+ malignancies.
机译:Wilms肿瘤蛋白(WT-1)被广泛认为是一种由几种恶性肿瘤差异表达的肿瘤抗原。然而,已知诱导肿瘤T细胞的WT-1肽很少。在本研究中,我们评估了56名健康供体对自体APC进行体外敏化的T细胞反应,这些APC上载有一系列跨越WT-1序列的15聚体重叠肽。此后,我们绘制了在每个个体中引起应答的WT-1肽图,定义了免疫原性肽,并鉴定了它们呈现的HLA等位基因。我们报告了WT-1先前未报告的表位:II类等位基因5个,I类等位基因36个,其中1个I类等位基因可能有10个。对98%的I类抗原表位和60%的II类抗原表位应答的IFNγ + T细胞均表现出对载肽靶标的HLA限制的细胞毒性。对36种WT-1肽具有特异性的T细胞可评估其杀白血病活性,其中27个(75%)裂解的WT-1 + 白血病靶标具有其限制性HLA等位基因。每个表位都在大多数共享表位呈递等位基因的供体中鉴定出诱导的T细胞反应。这些反应通常超过了对侧翼肽的免疫应答的预测。该系列的WT-1免疫原性表位应被证明可用于针对WT-1 + 恶性肿瘤的免疫治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号